Novo Nordisk, too, joined in the backlash, calling the commercial irresponsible and a ploy to drive sales of knockoff GLP-1 drugs
When Compounded Drugs Are Not Considered Copies The FDA recognizes three situations where a compounded drug will not be considered a copy of a commercially available product: The drug has been discontinued and is no longer marketed The drug is not readily available and is listed on the FDAs drug shortage list There is a specific change made for an identified patient whose medical needs cannot be met by the commercially available product [2] The Significant Difference Requirement For 503A compounding pharmacies, the third exception requires documentation that the prescriber has determined the compounded drug has a change that produces a significant difference for a specific patient
Here, we document the efficacy of such unimolecular GLP1 multi-agonists, and particularly the superiority of the GLP1/E conjugate, in managing the metabolic complications of PCOS in two mouse models of the disease, with evidence also for improvement of reproductive traits in an ovulatory model of PCOS
Potential risks to the infant should be weighed against the benefits for the mother
Some appetite changes, sleeping a bit deeper, nothing dramatic
